Authors
Latest:
Dr. Wong on Risk Factors for Hepatitis B-Associated HCCRobert Wong, MD, MS, assistant clinical professor of medicine, director of research and education, Division of Gastroenterology and Hepatology at Alameda Health System, Highland Hospital, discusses the risk factors of hepatitis B-associated hepatocellular carcinoma (HCC).
Latest:
Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MMThe relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.
Latest:
Dr. Leon Ferre on Reasons to Explore Biosimilars in OncologyRoberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.
Latest:
Dr. Bordonaro on the Treatment of Advanced CRCRoberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.
Latest:
Dr. Pili on the Challenges of Translocation RCCRoberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr Jones on Communication Between Community and Academic Oncologists in Cancer CareRobin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.
Latest:
Robin McConnell Discusses Nutrition in Cancer CareRobin McConnell, from John Theurer Cancer Center, Discusses Nutrition in Cancer Care
Latest:
Dr. Scherber Discusses Ruxolitinib Failure in MyelofibrosisRobyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses ruxolitinib (Jakafi) failure in patients with myelofibrosis (MF).
Latest:
Dr. Saw Discusses Study of Vitamin D in MelanomaRobyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.
Latest:
Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDACRocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.
Latest:
Dr. Amaria on Dabrafenib Plus Trametinib in MelanomaRodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.
Latest:
Dr. Amaria on Genetically Modified TILs in MelanomaRodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.
Latest:
Dr. Pommier Discusses Challenges Associated With the Treatment of Carcinoid SyndromeRodney F. Pommier, MD, professor of surgery, director, Neuroendocrine Tumor Program, Oregon Health & Science University, discusses challenges associated with the treatment of carcinoid syndrome.
Latest:
Dr. Goncalves on the ESR1 Mutation in Breast CancerRodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, describes research involving the ESR1 gene mutation in breast cancer.
Latest:
Novel Molecular Targets for Drug Development in Non-GIST SarcomasThe characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.
Latest:
Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade GliomasRoeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.
Latest:
Dr. Stupp on Final Results for TTFields Added to Chemo in GlioblastomaRoger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.
Latest:
Dr. Lilenbaum on the Rise of Immunotherapy in NSCLCRogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.
Latest:
Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLCRogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.
Latest:
Dr. Vivaldi on the Gaucher Disease TransformationDr. Rogerio Vivaldi the President of Genzyme Corporation on the Transformation of Gaucher Disease
Latest:
HIPEC for Ovarian Cancer: An Exciting Locoregional StrategyApproximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
Dr. Stahel on Treatment Sequencing in Stage IV NSCLCRolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.
Latest:
Dr. Perez-Soler on the Utility of Liquid Biopsy in Lung CancerRoman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.
Latest:
Dr. Ron Bose on HER2 Gene Mutations in Breast CancerRon Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.
Latest:
Dr. Natale on the Evolution of Immunotherapy in NSCLCRonald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.
